- Home
- TLPH vs TENX Comparison
TLPH vs TENX Comparison
Compare TLPH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- TENX
- Stock Information
- Founded
- TLPH 2005
- TENX 1967
- Country
- TLPH United States
- TENX United States
- Employees
- TLPH N/A
- TENX N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- TENX Health Care
- Exchange
- TLPH Nasdaq
- TENX Nasdaq
- Market Cap
- TLPH 64.7M
- TENX 31.9M
- IPO Year
- TLPH 2011
- TENX N/A
- Fundamental
- Price
- TLPH $1.31
- TENX $7.52
- Analyst Decision
- TLPH Strong Buy
- TENX Strong Buy
- Analyst Count
- TLPH 1
- TENX 2
- Target Price
- TLPH $6.00
- TENX $17.00
- AVG Volume (30 Days)
- TLPH 310.4K
- TENX 66.6K
- Earning Date
- TLPH 11-12-2025
- TENX 11-12-2025
- Dividend Yield
- TLPH N/A
- TENX N/A
- EPS Growth
- TLPH N/A
- TENX N/A
- EPS
- TLPH N/A
- TENX N/A
- Revenue
- TLPH $28,000.00
- TENX N/A
- Revenue This Year
- TLPH N/A
- TENX N/A
- Revenue Next Year
- TLPH $14,533.26
- TENX N/A
- P/E Ratio
- TLPH N/A
- TENX N/A
- Revenue Growth
- TLPH N/A
- TENX N/A
- 52 Week Low
- TLPH $0.38
- TENX $4.63
- 52 Week High
- TLPH $1.45
- TENX $8.24
- Technical
- Relative Strength Index (RSI)
- TLPH 56.55
- TENX 53.63
- Support Level
- TLPH $1.01
- TENX $6.60
- Resistance Level
- TLPH $1.35
- TENX $8.05
- Average True Range (ATR)
- TLPH 0.12
- TENX 0.42
- MACD
- TLPH -0.01
- TENX 0.03
- Stochastic Oscillator
- TLPH 75.61
- TENX 52.60
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.